Cargando…

QSAR, Molecular Docking, MD Simulation and MMGBSA Calculations Approaches to Recognize Concealed Pharmacophoric Features Requisite for the Optimization of ALK Tyrosine Kinase Inhibitors as Anticancer Leads

ALK tyrosine kinase ALK TK is an important target in the development of anticancer drugs. In the present work, we have performed a QSAR analysis on a dataset of 224 molecules in order to quickly predict anticancer activity on query compounds. Double cross validation assigns an upward plunge to the g...

Descripción completa

Detalles Bibliográficos
Autores principales: Jawarkar, Rahul D., Sharma, Praveen, Jain, Neetesh, Gandhi, Ajaykumar, Mukerjee, Nobendu, Al-Mutairi, Aamal A., Zaki, Magdi E. A., Al-Hussain, Sami A., Samad, Abdul, Masand, Vijay H., Ghosh, Arabinda, Bakal, Ravindra L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9370430/
https://www.ncbi.nlm.nih.gov/pubmed/35956900
http://dx.doi.org/10.3390/molecules27154951
_version_ 1784766794891788288
author Jawarkar, Rahul D.
Sharma, Praveen
Jain, Neetesh
Gandhi, Ajaykumar
Mukerjee, Nobendu
Al-Mutairi, Aamal A.
Zaki, Magdi E. A.
Al-Hussain, Sami A.
Samad, Abdul
Masand, Vijay H.
Ghosh, Arabinda
Bakal, Ravindra L.
author_facet Jawarkar, Rahul D.
Sharma, Praveen
Jain, Neetesh
Gandhi, Ajaykumar
Mukerjee, Nobendu
Al-Mutairi, Aamal A.
Zaki, Magdi E. A.
Al-Hussain, Sami A.
Samad, Abdul
Masand, Vijay H.
Ghosh, Arabinda
Bakal, Ravindra L.
author_sort Jawarkar, Rahul D.
collection PubMed
description ALK tyrosine kinase ALK TK is an important target in the development of anticancer drugs. In the present work, we have performed a QSAR analysis on a dataset of 224 molecules in order to quickly predict anticancer activity on query compounds. Double cross validation assigns an upward plunge to the genetic algorithm–multi linear regression (GA-MLR) based on robust univariate and multivariate QSAR models with high statistical performance reflected in various parameters like, fitting parameters; R(2) = 0.69–0.87, F = 403.46–292.11, etc., internal validation parameters; Q(2)(LOO) = 0.69–0.86, Q(2)(LMO) = 0.69–0.86, CCC(cv) = 0.82–0.93, etc., or external validation parameters Q(2)(F1) = 0.64–0.82, Q(2)(F2) = 0.63–0.82, Q(2)(F3) = 0.65–0.81, R(2)(ext) = 0.65–0.83 including RMSE(tr) < RMSE(cv). The present QSAR evaluation successfully identified certain distinct structural features responsible for ALK TK inhibitory potency, such as planar Nitrogen within four bonds from the Nitrogen atom, Fluorine atom within five bonds beside the non-ring Oxygen atom, lipophilic atoms within two bonds from the ring Carbon atoms. Molecular docking, MD simulation, and MMGBSA computation results are in consensus with and complementary to the QSAR evaluations. As a result, the current study assists medicinal chemists in prioritizing compounds for experimental detection of anticancer activity, as well as their optimization towards more potent ALK tyrosine kinase inhibitor.
format Online
Article
Text
id pubmed-9370430
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93704302022-08-12 QSAR, Molecular Docking, MD Simulation and MMGBSA Calculations Approaches to Recognize Concealed Pharmacophoric Features Requisite for the Optimization of ALK Tyrosine Kinase Inhibitors as Anticancer Leads Jawarkar, Rahul D. Sharma, Praveen Jain, Neetesh Gandhi, Ajaykumar Mukerjee, Nobendu Al-Mutairi, Aamal A. Zaki, Magdi E. A. Al-Hussain, Sami A. Samad, Abdul Masand, Vijay H. Ghosh, Arabinda Bakal, Ravindra L. Molecules Article ALK tyrosine kinase ALK TK is an important target in the development of anticancer drugs. In the present work, we have performed a QSAR analysis on a dataset of 224 molecules in order to quickly predict anticancer activity on query compounds. Double cross validation assigns an upward plunge to the genetic algorithm–multi linear regression (GA-MLR) based on robust univariate and multivariate QSAR models with high statistical performance reflected in various parameters like, fitting parameters; R(2) = 0.69–0.87, F = 403.46–292.11, etc., internal validation parameters; Q(2)(LOO) = 0.69–0.86, Q(2)(LMO) = 0.69–0.86, CCC(cv) = 0.82–0.93, etc., or external validation parameters Q(2)(F1) = 0.64–0.82, Q(2)(F2) = 0.63–0.82, Q(2)(F3) = 0.65–0.81, R(2)(ext) = 0.65–0.83 including RMSE(tr) < RMSE(cv). The present QSAR evaluation successfully identified certain distinct structural features responsible for ALK TK inhibitory potency, such as planar Nitrogen within four bonds from the Nitrogen atom, Fluorine atom within five bonds beside the non-ring Oxygen atom, lipophilic atoms within two bonds from the ring Carbon atoms. Molecular docking, MD simulation, and MMGBSA computation results are in consensus with and complementary to the QSAR evaluations. As a result, the current study assists medicinal chemists in prioritizing compounds for experimental detection of anticancer activity, as well as their optimization towards more potent ALK tyrosine kinase inhibitor. MDPI 2022-08-03 /pmc/articles/PMC9370430/ /pubmed/35956900 http://dx.doi.org/10.3390/molecules27154951 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Jawarkar, Rahul D.
Sharma, Praveen
Jain, Neetesh
Gandhi, Ajaykumar
Mukerjee, Nobendu
Al-Mutairi, Aamal A.
Zaki, Magdi E. A.
Al-Hussain, Sami A.
Samad, Abdul
Masand, Vijay H.
Ghosh, Arabinda
Bakal, Ravindra L.
QSAR, Molecular Docking, MD Simulation and MMGBSA Calculations Approaches to Recognize Concealed Pharmacophoric Features Requisite for the Optimization of ALK Tyrosine Kinase Inhibitors as Anticancer Leads
title QSAR, Molecular Docking, MD Simulation and MMGBSA Calculations Approaches to Recognize Concealed Pharmacophoric Features Requisite for the Optimization of ALK Tyrosine Kinase Inhibitors as Anticancer Leads
title_full QSAR, Molecular Docking, MD Simulation and MMGBSA Calculations Approaches to Recognize Concealed Pharmacophoric Features Requisite for the Optimization of ALK Tyrosine Kinase Inhibitors as Anticancer Leads
title_fullStr QSAR, Molecular Docking, MD Simulation and MMGBSA Calculations Approaches to Recognize Concealed Pharmacophoric Features Requisite for the Optimization of ALK Tyrosine Kinase Inhibitors as Anticancer Leads
title_full_unstemmed QSAR, Molecular Docking, MD Simulation and MMGBSA Calculations Approaches to Recognize Concealed Pharmacophoric Features Requisite for the Optimization of ALK Tyrosine Kinase Inhibitors as Anticancer Leads
title_short QSAR, Molecular Docking, MD Simulation and MMGBSA Calculations Approaches to Recognize Concealed Pharmacophoric Features Requisite for the Optimization of ALK Tyrosine Kinase Inhibitors as Anticancer Leads
title_sort qsar, molecular docking, md simulation and mmgbsa calculations approaches to recognize concealed pharmacophoric features requisite for the optimization of alk tyrosine kinase inhibitors as anticancer leads
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9370430/
https://www.ncbi.nlm.nih.gov/pubmed/35956900
http://dx.doi.org/10.3390/molecules27154951
work_keys_str_mv AT jawarkarrahuld qsarmoleculardockingmdsimulationandmmgbsacalculationsapproachestorecognizeconcealedpharmacophoricfeaturesrequisitefortheoptimizationofalktyrosinekinaseinhibitorsasanticancerleads
AT sharmapraveen qsarmoleculardockingmdsimulationandmmgbsacalculationsapproachestorecognizeconcealedpharmacophoricfeaturesrequisitefortheoptimizationofalktyrosinekinaseinhibitorsasanticancerleads
AT jainneetesh qsarmoleculardockingmdsimulationandmmgbsacalculationsapproachestorecognizeconcealedpharmacophoricfeaturesrequisitefortheoptimizationofalktyrosinekinaseinhibitorsasanticancerleads
AT gandhiajaykumar qsarmoleculardockingmdsimulationandmmgbsacalculationsapproachestorecognizeconcealedpharmacophoricfeaturesrequisitefortheoptimizationofalktyrosinekinaseinhibitorsasanticancerleads
AT mukerjeenobendu qsarmoleculardockingmdsimulationandmmgbsacalculationsapproachestorecognizeconcealedpharmacophoricfeaturesrequisitefortheoptimizationofalktyrosinekinaseinhibitorsasanticancerleads
AT almutairiaamala qsarmoleculardockingmdsimulationandmmgbsacalculationsapproachestorecognizeconcealedpharmacophoricfeaturesrequisitefortheoptimizationofalktyrosinekinaseinhibitorsasanticancerleads
AT zakimagdiea qsarmoleculardockingmdsimulationandmmgbsacalculationsapproachestorecognizeconcealedpharmacophoricfeaturesrequisitefortheoptimizationofalktyrosinekinaseinhibitorsasanticancerleads
AT alhussainsamia qsarmoleculardockingmdsimulationandmmgbsacalculationsapproachestorecognizeconcealedpharmacophoricfeaturesrequisitefortheoptimizationofalktyrosinekinaseinhibitorsasanticancerleads
AT samadabdul qsarmoleculardockingmdsimulationandmmgbsacalculationsapproachestorecognizeconcealedpharmacophoricfeaturesrequisitefortheoptimizationofalktyrosinekinaseinhibitorsasanticancerleads
AT masandvijayh qsarmoleculardockingmdsimulationandmmgbsacalculationsapproachestorecognizeconcealedpharmacophoricfeaturesrequisitefortheoptimizationofalktyrosinekinaseinhibitorsasanticancerleads
AT ghosharabinda qsarmoleculardockingmdsimulationandmmgbsacalculationsapproachestorecognizeconcealedpharmacophoricfeaturesrequisitefortheoptimizationofalktyrosinekinaseinhibitorsasanticancerleads
AT bakalravindral qsarmoleculardockingmdsimulationandmmgbsacalculationsapproachestorecognizeconcealedpharmacophoricfeaturesrequisitefortheoptimizationofalktyrosinekinaseinhibitorsasanticancerleads